Advances in research of PARP inhibitors in combination with chemotherapeutic agents in the treatment of malignant tumors / 肿瘤

ABSTRACT

In recent years, synthetic lethality of PARP [poly (ADP-ribose) polymerase] inhibition in cancers with BRCA1 (breast cancer susceptibility gene 1) and BRCA2 mutations appears to provide a novel, efficient and safe antitumor strategy. It was hypothesized that the mechanism underlying this new antitumor strategy was the inhibition of DNA damage repair leading to cell death. Since the synthetic lethality was confirmed in breast cancer cells by PARP inhibitor intervention, many highly selective and sensitive PARP inhibitors have been developed and applied in clinical trials. Although the effectiveness of PARP inhibitor used as a single agent can be reached in breast cancer and ovarian cancer with BRCA1 / BRCA2 mutation, it is generally advised to use PARP inhibitors in combination with chemotherapeutic agents or radiation therapy. This review is focused on the recent progress in clinical antitumor therapy with PARP inhibitors in combination with common chemotherapeutic agents. Copyright © 2013 by TUMOR.